Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reaction Biology Top-Ranked in Kinase Profiling Survey

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
RBC also ranked highly on technical support and data quality.

Reaction Biology Corporation ("RBC") has announced that it has received the highest number of positive ratings in a recent industry survey.

HTStec, a UK-based technical research firm, surveyed 78 research labs around the globe for its Kinase Profiling Trends 2013 report. The labs included large pharmas, biotechs, university and non-profit labs.

Survey participants were asked to rate the 16 top kinase profiling outsource providers on eight different attributes.

The provider with the highest number of positive ratings was RBC, which came in number one on customer service, turnaround time, and low cost.

RBC also ranked as the most-used provider to the industry, rising from fifth place in the same survey taken in 2010.

“We are very pleased with this validation of our efforts to provide the widest coverage of the kinome, with a gold standard activity assay,” said Dr. Haiching Ma, Chief Science Officer of RBC.

Dr. Ma continued, “Eighty-eight percent of all pharmas in the survey preferred activity-based assays, and RBC’s radiolabeled HotSpot assay now provides high-quality reproducible data on 457 kinases.”

The survey estimated that RBC had the largest share of the $34 million kinase profiling market.

Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With more than 450 kinases, RBC’s coverage of the kinome is the broadest in the industry.

Using its proprietary HotSpotSM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.

RBC has provided its services to over 300 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reaction Biology and Cisbio Sign Distribution Agreement
Agreement will see Cisbio distribute Reaction Biology's epigenetic proteins.
Friday, January 17, 2014
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!